Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
List view / Grid view
Filter the results
The patent office has declared an interference between 10 University of California (UC) patent applications.
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
Cardio3 BioSciences receives Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors designed for the topical treatment of retinal disease
8 December 2014 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166...
Gilead announces new agreement with Medicines Patent Pool for access to medicines in developing world countries
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...